ARTICLE | Clinical News
Arzerra ofatumumab: Phase III data
May 4, 2015 7:00 AM UTC
Top-line data from the open-label, international Phase III COMPLEMENT 2 trial in 365 patients with relapsed CLL showed that IV Arzerra plus fludarabine and cyclophosphamide met the primary endpoint o...